Biotech News

Minerva Neurosciences to Participate in Two Upcoming Investor Conferences

Minerva Neuroscience (NERV)Minerva NeuroscienceClinical readout

Minerva Neurosciences, Inc. (Nasdaq: NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervous system disorders, today announced that management will participate in two upcoming investor conferences.

Wells Fargo Healthcare Conference Date: Tuesday, September 8 Format: 1x1 meetings Location: New York, NY

2026 Cantor Global Healthcare Conference Date: Wednesday, September 9 Format: Fireside chat and 1x1 meetings Time: 2:45 – 3:15 PM EDT Location: New York, NY

If you are interested in meeting with the Minerva team during the conferences, please reach out to your respective conference representative.

The live webcast can be accessed in the events section of the Minerva Neurosciences website HERE . Access to the webcast replay will be available approximately two hours after the completion of the events and will be archived on the Company’s website.

About Minerva Neurosciences

Minerva Neurosciences, Inc. is a clinical-stage biopharmaceutical company focused on developing product candidates to treat CNS diseases. Minerva is conducting a confirmatory Phase 3 trial with roluperidone for negative symptoms of schizophrenia. For more information, please visit the Company’s website .

Contacts: Frederick Ahlholm Chief Financial Officer Minerva Neurosciences, Inc. FAhlholm@minervaneurosciences.com

Corey Davis, Ph.D. LifeSci Advisors, LLC 212-915-2577 [email protected]

Related news

NERVMinerva Neuroscience2026-10-29 11:00 EST

Minerva Neurosciences to Participate in 2026 Jefferies Global Healthcare Conference in London

NERVMinerva Neuroscience2026-10-28 11:00 EST

Minerva Neurosciences to Host In-Person KOL Event to Discuss Roluperidone for Negative Symptoms of Schizophrenia

ANNXAnnexon, Inc.2026-10-28 12:01 EST

Annexon to Host Virtual Investor Event on November 3, 2026: Vonaprument for the Treatment of Geographic Atrophy - Highlighting Key Aspects of Phase 3 ARCHER II Trial

ANVSAnnovis Bio2026-11-17 13:00 EST

Annovis Receives Second Positive DSMB Recommendation for its Phase 3 DUET-AD Study

ANVSAnnovis Bio2026-11-12 13:00 EST

Annovis Bio Granted U.S. Patent Covering New Crystalline Form of Buntanetap

TEVATeva Pharmaceutical Industries2026-11-02 13:00 EST

Teva to Discontinue Phase 2 TOPAS-MSA Study of emrusolmin (TEV-‘286) Following Interim Futility Analysis

ABOSAcumen Pharmaceuticals2026-10-30 11:00 EST

Acumen Pharmaceuticals Announces Topline Results from Phase 2 ALTITUDE-AD Clinical Trial of Sabirnetug (ACU193) for the Treatment of Early Alzheimer’s Disease; Trial Did Not Meet Primary Endpoint

ALKSAlkermes plc2026-10-30 11:00 EST

Alkermes Expands ALKS 7290 Development Program With Initiation of Phase 2 Study for the Adjunctive Treatment of Major Depressive Disorder (MDD)

XENEXenon2026-10-29 12:30 EST

Xenon Announces Positive Phase 1 and New Preclinical Data at IASP 2026 Supporting Advancement of XEN1701 and XEN1120 to Phase 2 Proof-of-Concept Studies in Acute Pain

JNJJohnson & Johnson2026-10-25 14:24 EST

Subcutaneous RYBREVANT®▼ (amivantamab) demonstrates 77% overall response rate in first-line treatment of patients with certain types of advanced head and neck cancer

Minerva Neuroscience

CNS Drug Development Minerva Neurosciences develops therapies for central nervous system disorders. Its lead program focuses specifically on negative symptoms of schizophrenia, an area with limited approved treatment options. Roluperidone Roluperidone is an investigational oral therapy intended to improve primary negative symptoms such...

Recent company news

Stock data

Close
2.12 USD
Market cap
221.3M USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States